FDA Ends Ban Of Claris Lifesciences Products

Law360, Washington (August 20, 2012, 7:30 PM EDT) -- Claris Lifesciences Ltd. has received word from the U.S. Food and Drug Administration that it has adequately cleared up injectable-drug contamination issues and factory violations that resulted in a 2010 warning letter and import ban, the company announced Thursday.

In a closeout letter posted on the FDA website, the agency noted the Indian sterile-injectable maker had made the necessary changes to resolve the issues noted in its November 2010 warning letter, which said Claris' factory in Ahmedabad, India, took a lax attitude to safety that allowed...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.